Starpharma Holdings (ASX:SPL) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

SPL Stoklara Genel Bakış

SPL temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 6.5% oranında arttı

Risk Analizi

Anlamlı bir piyasa değeri yok ( A$42M )

Starpharma Holdings Limited Rakipler

Vitura Health

ASX:VIT

AU$43.8m

Cann Group

ASX:CAN

AU$32.4m

Little Green Pharma

ASX:LGP

AU$24.7m

Medical Developments International

ASX:MVP

AU$57.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Starpharma Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.097
52 Haftanın En Yüksek Seviyesi	AU$0.20
52 Haftanın En Düşük Seviyesi	AU$0.086
Beta	0.77
11 Aylık Değişim	2.11%
3 Aylık Değişim	-2.02%
1 Yıllık Değişim	-28.15%
33 Yıllık Değişim	-92.05%
5 Yıllık Değişim	-91.53%
Halka arzdan bu yana değişim	-87.88%

Son Haberler & Güncellemeler

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18

Recent updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07

Hissedar Getirileri

	SPL	AU Pharmaceuticals	AU Pazar
7D	-2.0%	-6.3%	-0.7%
1Y	-28.1%	82.1%	17.1%

Getiri vs. Endüstri: SPL geçen yıl % 98.5 oranında getiri sağlayan Australian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: SPL geçen yıl % 17.9 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is SPL's price volatile compared to industry and market?
SPL volatility
SPL Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: SPL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: SPL 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	40	Cheryl Maley	starpharma.com

Bir biyofarmasötik şirketi olan Starpharma Holdings Limited, dünya çapında farmasötik, yaşam bilimleri ve diğer uygulamalar için dendrimer ürünlerinin araştırılması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Şirketin ürünleri arasında bakteriyel vajinozis (BV) tedavisi ve tekrarlayan BV'nin önlenmesi için antibiyotik olmayan bir vajinal jel olan VivaGel BV; antiviral bir burun spreyi olan VIRALEZE; ve antiviral bir prezervatif kaplaması olan VivaGel prezervatif bulunmaktadır. Ayrıca, Faz II klinik çalışmasında olan yumurtalık ve kolorektal kanser tedavisi için DEP SN38; Faz II klinik çalışmasında olan prostat ve yumurtalık kanseri tedavisi için DEP cabazitaxel; ve Faz II klinik çalışmasında olan pankreas ve diğer kanserleri tedavi etmek için DEP docetaxel'den oluşan dendrimer geliştirilmiş ürün (DEP) dağıtım platformunun geliştirilmesinde yer almaktadır.

Starpharma Holdings Limited Temel Bilgiler Özeti

Starpharma Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SPL temel i̇stati̇sti̇kler
Piyasa değeri	AU$40.48m
Kazançlar(TTM)	-AU$8.16m
Gelir(TTM)	AU$9.76m

4.1x

P/S Oranı

-5.0x

F/K Oranı

SPL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SPL gelir tablosu (TTM)
Gelir	AU$9.76m
Gelir Maliyeti	AU$10.69m
Brüt Kâr	-AU$929.00k
Diğer Giderler	AU$7.24m
Kazançlar	-AU$8.16m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.02
Brüt Marj	-9.52%
Net Kâr Marjı	-83.69%
Borç/Özkaynak Oranı	2.8%

SPL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

SPL Stoklara Genel Bakış

Ödüller

Risk Analizi

Starpharma Holdings Limited Rakipler

ASX:VIT

AU$43.8m

ASX:CAN

AU$32.4m

ASX:LGP

AU$24.7m

ASX:MVP

AU$57.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Recent updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Releases New Data About SPL7013

Forecast to breakeven in 2022

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Starpharma Signs DEP ADC Research Agreement with MSD

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.80

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Price target raised to AU$2.03

New 90-day high: AU$1.68

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?